52-week open-label extension confirmed sustained oral semaglutide safety and efficacy, with continued HbA1c and weight benefits and no new safety signals over extended treatment.
A year more of safety52 additional weeks of oral semaglutide showed sustained benefits and no new safety concerns — confirming long-term suitability
What the researchers found
52-week extension: sustained oral semaglutide HbA1c and weight benefits with consistent safety and no new safety signals over extended treatment period.
Why it matters
Diabetes and obesity are lifelong conditions. Confirming 52+ weeks of safe, effective oral semaglutide supports long-term prescribing confidence.
How the study worked
52-week open-label extension study of oral semaglutide safety and efficacy in patients completing initial clinical trials.
What this study cannot tell us
Open-label (no blinding). Extension study population may be self-selected (tolerant, responsive). Sample in full paper.
How to read the evidence
Open-label extension study. Standard for long-term safety assessment.
When this study was published
Published in 2025.
The bigger picture
Long-term extension data provides the safety foundation for indefinite oral semaglutide use in chronic metabolic disease.
Questions still open
- Are benefits sustained beyond 52 additional weeks?
- Does long-term oral semaglutide affect absorption of other oral medications?
- Would switching from injectable to oral semaglutide maintain effects long-term?
Common questions
Is oral semaglutide safe for long-term use?
Do the benefits last over a year?
Read the original research
A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.
Headache, 66(2), 407-416
Citation
Kudrow, David; Croop, Robert S; Thiry, Alexandra; Lipton, Richard B. (2026). A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.. Headache, 66(2), 407-416. https://doi.org/10.1111/head.15002